Neoleukin Therapeutics (NASDAQ:NLTX) Downgraded to “Sell” at ValuEngine
Shares of NASDAQ NLTX opened at $5.23 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 26.35 and a current ratio of 26.35. Neoleukin Therapeutics has a one year low of $2.00 and a one year high of $6.59. The company’s fifty day moving average price is $3.39.
Neoleukin Therapeutics (NASDAQ:NLTX) last announced its quarterly earnings data on Wednesday, November 13th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.40).
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.
Featured Article: How much can an individual set aside as a catch-up contribution?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.